98%
921
2 minutes
20
Background: We explored syringe service program (SSP) perspectives on barriers, readiness, and programmatic needs to support coronavirus disease 2019 (COVID-19) vaccine uptake among people who use drugs.
Methods: We conducted an exploratory qualitative study, leveraging an existing sample of SSPs in the United States. Semistructured, in-depth interviews were conducted with SSP staff between February and April 2021. Interviews were analyzed using a Rapid Assessment Process, an intensive, iterative process that allows for rapid analysis of time-sensitive qualitative data.
Results: Twenty-seven SSPs completed a qualitative interview. Many SSP respondents discussed that COVID-19 vaccination was not a priority for their participants because of competing survival priorities, and respondents shared concerns that COVID-19 had deepened participant mistrust of health care. Most SSPs wanted to participate in COVID-19 vaccination efforts; however, they identified needed resources, including adequate space, personnel, and training, to implement successful vaccine programs.
Conclusions: Although SSPs are trusted resources for people who use drugs, many require additional structural and personnel support to address barriers to COVID-19 vaccination among their participants. Funding and supporting SSPs in the provision of COVID-19 prevention education and direct vaccine services should be a top public health priority.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892351 | PMC |
http://dx.doi.org/10.1097/ADM.0000000000001036 | DOI Listing |
Mol Biol Rep
September 2025
School of Arts and Sciences, Department of Natural and Applied Sciences, The American University of Iraq-Baghdad, Baghdad, Iraq.
The COVID-19 pandemic, caused by the continuously evolving SARS-CoV-2 virus, has presented persistent global health challenges. As novel variants emerge, many with enhanced transmissibility and immune evasion capabilities, concerns have intensified regarding the efficacy of existing vaccines and therapeutics. This review provides a comprehensive overview of the current landscape of COVID-19 vaccination, including the development and performance of monovalent and bivalent boosters, and examines their effectiveness against newly emerging variants of interest (VOIs) and variants under monitoring (VUMs), such as JN.
View Article and Find Full Text PDFDev World Bioeth
September 2025
Faculty of Law, University of Alberta, Edmonton, Alberta, Canada.
This article explores two complementary strategies for addressing the affordability and access challenges facing advanced therapies. As high development costs and limited market access have led to the withdrawal of several therapies, the article examines how these barriers create 'valleys of death' that prevent innovation from reaching patients. Through the case of Glybera and other examples, it outlines a rehabilitative approach focused on reforming current systems through improved reimbursement schemes, regulatory streamlining, and more efficient manufacturing.
View Article and Find Full Text PDFPediatr Infect Dis J
September 2025
Hospital Universitario "Dr. José Eleuterio González," Monterrey, México.
We analyzed 59 pediatric pertussis cases during Mexico's 2024-2025 outbreak. Mortality was 13.6%, with low maternal Tdap coverage (27.
View Article and Find Full Text PDFInfect Control Hosp Epidemiol
September 2025
Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Background: Admission to shared hospital rooms are a risk factor of healthcare-associated (HA) SARS-CoV-2. Quantifying the impact of engineering controls such as ventilation and filtration is essential to informing resource utilization and infection prevention guidelines.
Methods: Multicenter test-negative study of patients exposed to SARS-CoV-2 in shared rooms across five hospitals between January and October, 2022.
Psychol Health
September 2025
Institute of Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK.
Objective: There is a lack of research on how illness representations as represented in the Common Sense Self-Regulation Model (CS-SRM) emerge and develop. We aimed to describe the evolution of COVID-19 illness representations over time, and to explore associations with sociodemographic characteristics and protective behaviours.
Methods And Measures: This study (June 2020 release from lockdown to February 2021 after vaccine roll-out) used 17 independently recruited cross-sectional cohorts.